August 2016
www.fda.gov/womens
Public Workshop: Diabetes Outcome Measures Beyond Hemoglobin A1c (HbA1c)
On August 29, 2016, FDA’s Center for Drug Evaluation and Research (CDER), is sponsoring a public workshop entitled “Diabetes Outcome Measures Beyond Hemoglobin A1c (HbA1c).”
The purpose of this public workshop is to have a forum for dialogue on the extent to which the current regulatory paradigm for antidiabetic drug therapies addresses the needs of patients with diabetes and to identify additional outcomes, beyond HbA1c.
No hay comentarios:
Publicar un comentario